Therapeutic management of advanced Adrenocortical carcinoma: What do we know in 2011?

Hormones and Cancer

Volumn 2, Issue 6, 2011, Pages 363-371

  Baudin, E ^a,b   Leboulleux, S ^a,b   Al Ghuzlan, A ^a,b   Chougnet, C ^a,b   Young, J ^a,b   Deandreis, D ^a,b   Dumont, F ^a,b   Dechamps, F ^a,b   Caramella, C ^a,b   Chanson, P ^b,c   Lanoy, E ^a,b   Borget, I ^a,b   Schlumberger, M ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Institut National de la Sante et de la Recherche Medicale U693 ^*  (France)

Author keywords

Adrenocortical carcinoma; Predictive markers surrogates; Prognosis; Treatment

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TARGETING; HORMONE INHIBITION; HUMAN; MONOTHERAPY; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SOMNOLENCE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; VERTIGO;

ADRENAL GLAND NEOPLASMS; ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ADENOID CYSTIC; CISPLATIN; CLINICAL TRIALS AS TOPIC; HUMANS; MITOTANE; NEOPLASM STAGING; PROGNOSIS; TUMOR BURDEN;

EID: 83955165239     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0094-2     Document Type: Article

References (55)

1. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B (2009) 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115: 243-250.
2. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25: 891-897.
3. Lughezzani G, Sun M, Perrot P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI (2010) The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system. Eur J Cancer 46: 713-719.
4. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M, Baudin E (2007) Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92: 148-154.
5. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, Gilchrist KW, Horton J (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110: 1006-1013.
6. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11: 161-165.
7. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94: 2333-2343.
8. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17: 797-807.
9. Fareau GG, Lopez A, Stava C, Vassilopoulou-Sellin R (2008) Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs 19: 637-644.
10. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K, Eriksson B (2000) Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11: 1281-1287.
11. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657-666.
12. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA (1989) Adrenal cortical carcinoma. Cancer 64: 765-769.
13. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-1201.
14. Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112: 963-970.
15. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69: 947-951.
16. Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M (1997) Adrenocortical carcinoma: experience in 45 patients. Oncology 54: 490-496.
17. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study. Cancer 88(5): 1159-1165.
18. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M (2001) Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 1385-1392.
19. Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, Terzolo M, Berruti A, Papotti M (2009) Histopathol 55: 53-54.
20. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20: 941-950.
21. Miller BS, Gauger PG, Hammer G, Giordano T, Doherty GM (2010) Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 34: 1380-1387.
22. Soreide JA, Brabrand K, Thoresen SO (1992) Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 16: 663-667.
23. Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin, Gagel RF, Burgess A, Evans DB (1995) Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118: 1090-1098.
24. Schulick RD, Brennan MF (1999) Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6: 719-726.
25. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C (2008) Cancer 13: 3130-3136.
26. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91: 2650-2655.
27. Ronchi C, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg H, Hahner S, Allolio B, Fassnacht M (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16: 907-918.
28. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammmer G (2009) Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15: 668-676.
29. de Reynies A, Assié G, Rickman DS, Tissier F, Groussin L, Rné-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identified molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115.
30. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M (2010) High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 95: 161-171.
31. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audbourg A, Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J (2010) β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cacer Res 17: 328-336.
32. Fenske W, Volker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Muller-Hermelink, Allolio B, Fassnacht M (2009) Glucose transporter GLUT 1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 16(3): 919-928.
33. Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91: 920-925.
34. Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, Brailly-Tabard S, Leboulleux S, Schlumberger M, Baudin E, Chanson P, Young J (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 96: 2796-2804.
35. Veytsman I, Nieman L, Fojo T (2009) Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 27: 1-14.
36. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endoc 75: 585-591.
37. Cazejust J, De Baere T, Auperin A, Deschamps F, Hechelhammer, Abdel-rehim M, Schlumberger M, Leboulleux S, Baudin E (2010) Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. Int Vasc Radiol 94: 204-210.
38. Nelson AA, Woodard G (1949) Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2, 2-bis(parachlorophenyl)-1, 1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 48: 387-394.
39. Hutter AM Jr, Kayhoe DE (1966) Adrenal cortical carcinoma. Results of treatment with o, p'DDD in 138 patients. Am J Med 41(4): 581-592.
40. Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Oden A, Ahlman H (2010) The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17: 265-272.
41. Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96: 1844-1851.
42. Bates SE, Shieh CY, Mickley LA et al (1991) Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73(1): 18-29.
43. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15: 1043-1053.
44. Baudin E, Docao C, Gicquel C, Vassal G, Bachelot A, Penfornis A, Schlumberger M (2002) Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 13: 1806-1809.
45. Burgess MA, Legha SS, Sellin RV (1983) Chemotherapy with cisplatinum and etoposide (VP16) for patients with advanced adrenal cortical carcinoma. ASCO proceedings: A5.
46. van Slooten HMA, van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o, p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20(1): 47-52.
47. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67: 2997-3000.
48. Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux AF, Nakib I, Schlumberger M, Reseau Comete INSERM (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 78: 546-549.
49. Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K, Eriksson E (2004) Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical carcinoma. Medical Oncol 21: 167-177.
50. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17: 445-453.
51. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammerr GD, Korobkin M, Worden FP (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12: 667-680.
52. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o, p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20: 47-53.
53. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L, Angeli A (2000) Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85: 2234-2238.
54. Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E (2006) Rapidly progressing high o, p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol 64: 110-113.
55. Gonzales RJ, Tamm EP, Chaan Ng, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE (2007) Response to mitotane therapy predicts outcome in patients with recurrent adrenal cortical carcinoma. Sugery 142: 867-875.